Reelin Signaling in Oligodendrocyte Progenitor Cell Migration
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Identification of an Alpha-1 Antitrypsin Variant with Enhanced Specificity For
www.nature.com/scientificreports OPEN Identifcation of an alpha‑1 antitrypsin variant with enhanced specifcity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis Varsha Bhakta1, Mostafa Hamada2, Amy Nouanesengsy2, Jessica Lapierre2, Darian L. Perruzza2 & William P. Shefeld1,2* Coagulation Factor XIa (FXIa) is an emerging target for antithrombotic agent development. The M358R variant of the serpin alpha‑1 antitrypsin (AAT) inhibits both FXIa and other proteases. Our aim was to enhance the specifcity of AAT M358R for FXIa. We randomized two AAT M358R phage display libraries at reactive centre loop positions P13‑P8 and P7‑P3 and biopanned them with FXIa. A bacterial expression library randomized at P2′‑P3′ was also probed. Resulting novel variants were expressed as recombinant proteins in E. coli and their kinetics of FXIa inhibition determined. The most potent FXIa‑inhibitory motifs were: P13‑P8, HASTGQ; P7‑P3, CLEVE; and P2‑P3′, PRSTE (respectively, novel residues bolded). Selectivity for FXIa over thrombin was increased up to 34‑fold versus AAT M358R for these single motif variants. Combining CLEVE and PRSTE motifs in AAT‑RC increased FXIa selectivity for thrombin, factors XIIa, Xa, activated protein C, and kallikrein by 279‑, 143‑, 63‑, 58‑, and 36‑fold, respectively, versus AAT M358R. AAT‑RC lengthened human plasma clotting times less than AAT M358R. AAT‑RC rapidly and selectively inhibits FXIa and is worthy of testing in vivo. AAT specifcity can be focused on one target protease by selection in phage and bacterial systems coupled with combinatorial mutagenesis. Trombosis, the blockage of intact blood vessels by occlusive clots, continues to impose a heavy clinical burden, and is responsible for one quarter of deaths world-wide1. -
Reelin Is Preferentially Expressed in Neurons Synthesizing ␥-Aminobutyric Acid in Cortex and Hippocampus of Adult Rats
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 3221–3226, March 1998 Neurobiology Reelin is preferentially expressed in neurons synthesizing g-aminobutyric acid in cortex and hippocampus of adult rats C. PESOLD*†,F.IMPAGNATIELLO*, M. G. PISU*, D. P. UZUNOV*, E. COSTA*, A. GUIDOTTI*, AND H. J. CARUNCHO*‡ *Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612; and ‡Department of Morphological Sciences, University of Santiango de Compostela School of Medicine, 15705 Santiago de Compostela, Spain Contributed by Erminio Costa, December 24,1997 ABSTRACT During embryonic development of brain lam- sion, prevent Reelin transcription or secretion (4, 12, 14). In inated structures, the protein Reelin, secreted into the extracel- the cortex and hippocampus of rat embryos, Reelin begins to lular matrix of the cortex and hippocampus by Cajal–Retzius be synthesized in Cajal–Retzius (CR) cells from embryonic day (CR) cells located in the marginal zone, contributes to the 13 to the second postnatal week, and in the cerebellum Reelin regulation of migration and positioning of cortical and hip- is expressed first in the external granule cell layer (EGL) pocampal neurons that do not synthesize Reelin. Soon after before the granule cell migration to the internal granule cell birth, the CR cells decrease, and they virtually disappear during layer (IGL) (2, 15–17). When the CR50 antibody is added to the following 3 weeks. Despite their disappearance, we can embryonic preparations expressing normal histogenetic pat- quantify Reelin mRNA (approximately 200 amolymg of total terns of lamination, it induces typical histogenetic abnormal- RNA) and visualize it by in situ hybridization, and we detect the ities of the Relnrl phenotype (7, 9, 10, 17). -
Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders
fncel-14-00285 August 31, 2020 Time: 14:32 # 1 ORIGINAL RESEARCH published: 02 September 2020 doi: 10.3389/fncel.2020.00285 Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders Daisuke Ibi1*†, Genki Nakasai1†, Nayu Koide1†, Masahito Sawahata2, Takao Kohno3, Rika Takaba1, Taku Nagai2,4, Mitsuharu Hattori3, Toshitaka Nabeshima5, Kiyofumi Yamada2* and Masayuki Hiramatsu1 1 Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 2 Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3 Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan, 4 Project Office for Neuropsychological Research Center, Fujita Health University, Toyoake, Japan, 5 Advanced Diagnostic System Research Laboratory, Fujita Health University, Graduate School of Health Sciences, Toyoake, Japan Edited by: Marie-Eve Tremblay, In the majority of schizophrenia patients, chronic atypical antipsychotic administration University of Victoria, Canada produces a significant reduction in or even complete remission of psychotic symptoms Reviewed by: such as hallucinations and delusions. However, these drugs are not effective in Dilja Krueger-Burg, improving cognitive and emotional deficits in patients with schizophrenia. Atypical University Medical Center Göttingen, Germany antipsychotic drugs have a high affinity for the dopamine D2 receptor, and a José M. Delgado-García, -
Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders
Hindawi Publishing Corporation Autism Research and Treatment Volume 2012, Article ID 868576, 6 pages doi:10.1155/2012/868576 Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders Naghi Momeni,1 Lars Brudin,2 Fatemeh Behnia,3 Berit Nordstrom,¨ 4 Ali Yosefi-Oudarji,5 Bengt Sivberg,4 Mohammad T. Joghataei,5 and Bengt L. Persson1 1 School of Natural Sciences, Linnaeus University, 39182 Kalmar, Sweden 2 Department of Clinical Physiology, Kalmar County Hospital, 39185 Kalmar, Sweden 3 Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4 Department of Health Sciences, Autism Research, Faculty of Medicine, Lund University, Box 157, 22100 Lund, Sweden 5 Cellular and Molecular Research Centre, Tehran University of Medical Sciences (TUMS), Tehran, Iran Correspondence should be addressed to Bengt Sivberg, [email protected] Received 17 June 2011; Revised 22 August 2011; Accepted 22 August 2011 Academic Editor: Judy Van de Water Copyright © 2012 Naghi Momeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autism spectrum disorders (ASDs) are neurodevelopmental and behavioural syndromes affecting social orientation, behaviour, and communication that can be classified as developmental disorders. ASD is also associated with immune system abnormality. Im- mune system abnormalities may be caused partly by complement system factor I deficiency. Complement factor I is a serine pro- tease present in human plasma that is involved in the degradation of complement protein C3b, which is a major opsonin of the complement system. -
Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: a Comparative in Situ Hybridization Analysis
The Journal of Neuroscience, March 1993. 73(3): 1258-1279 Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: A Comparative in situ Hybridization Analysis Martin K.-H. Schafer,i-a Robert Day,* William E. Cullinan,’ Michel Chri?tien,3 Nabil G. Seidah,* and Stanley J. Watson’ ‘Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0720 and J. A. DeSeve Laboratory of *Biochemical and 3Molecular Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada H2W lR7 Posttranslational processing of proproteins and prohor- The participation of neuropeptides in the modulation of a va- mones is an essential step in the formation of bioactive riety of CNS functions is well established. Many neuropeptides peptides, which is of particular importance in the nervous are synthesized as inactive precursor proteins, which undergo system. Following a long search for the enzymes responsible an enzymatic cascade of posttranslational processing and mod- for protein precursor cleavage, a family of Kexin/subtilisin- ification events during their intracellular transport before the like convertases known as PCl, PC2, and furin have recently final bioactive products are secreted and act at either pre- or been characterized in mammalian species. Their presence postsynaptic receptors. Initial endoproteolytic cleavage occurs in endocrine and neuroendocrine tissues has been dem- C-terminal to pairs of basic amino acids such as lysine-arginine onstrated. This study examines the mRNA distribution of (Docherty and Steiner, 1982) and is followed by the removal these convertases in the rat CNS and compares their ex- of the basic residues by exopeptidases. Further modifications pression with the previously characterized processing en- can occur in the form of N-terminal acetylation or C-terminal zymes carboxypeptidase E (CPE) and peptidylglycine a-am- amidation, which is essential for the bioactivity of many neu- idating monooxygenase (PAM) using in situ hybridization ropeptides. -
Proquest Dissertations
urn u Ottawa L'Universitd canadienne Canada's university FACULTE DES ETUDES SUPERIEURES l^^l FACULTY OF GRADUATE AND ET POSTDOCTORALES u Ottawa POSTDOCTORAL STUDIES I.'University emiadienne Canada's university Charles Gyamera-Acheampong AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Biochemistry) GRADE/DEGREE Biochemistry, Microbiology and Immunology FACULTE, ECOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT The Physiology and Biochemistry of the Fertility Enzyme Proprotein Convertase Subtilisin/Kexin Type 4 TITRE DE LA THESE / TITLE OF THESIS M. Mbikay TIRECTWRTDIRICTR^ CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS A. Basak G. Cooke F .Kan V. Mezl Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59504-6 Our file Notre reference ISBN: 978-0-494-59504-6 NOTICE: AVIS: The author has granted a non L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. -
Reelin Gene Polymorphisms in Autistic Disorder
Chapter 25 Reelin Gene Polymorphisms in Autistic Disorder Carla Lintas and Antonio Maria Persico Contents 1 Introduction ....................................................................................................................... 385 2 RELN Gene Polymorphisms and Autism .......................................................................... 386 3 Functional Studies of RELN GGC Alleles ........................................................................ 389 4 RELN GGC Alleles and Autism: Replication Studies ....................................................... 390 5 Modeling RELN Gene Contributions to Autism: The Challenge of Complexity .............. 394 References ............................................................................................................................... 396 1 Introduction Migratory streams occur throughout the central nervous system (CNS) during devel- opment. Neuronal and glial cell populations migrate out of proliferative zones to reach their final location, where neurons soon establish early intercellular connec- tions. Reelin plays a pivotal role in cell migration processes, acting as a stop signal for migrating neurons in several CNS districts, including the neocortex, the cerebel- lum, and the hindbrain (Rice and Curran, 2001). At the cellular level, Reelin acts by binding to a variety of receptors, including the VLDL receptors, ApoER2, and α3β1 integrins, and also by exerting a proteolytic activity on extracellular matrix proteins, which is critical to neuronal migration -
Reelin, a Marker of Stress Resilience in Depression and Psychosis
Neuropsychopharmacology (2011) 36, 2371–2372 & 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 www.neuropsychopharmacology.org Commentary Reelin, a Marker of Stress Resilience in Depression and Psychosis ,1,2 S Hossein Fatemi* 1 2 Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA; Departments of Neuroscience and Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA Neuropsychopharmacology (2011) 36, 2371–2372; doi:10.1038/npp.2011.169 Reelin protein is an extracellular matrix protease respon- common phenomena subserving cognitive deficits in multi- sible for normal lamination of the brain during embryo- ple disorders including lissencephaly, Alzheimer’s disease, genesis, and is involved in cell signaling and synaptic and temporal lobe epilepsy. The causative factors may plasticity in adult life. The Reelin gene (RELN) is localized include a mutation in the RELN gene (lissencephaly) to to chromosome 7 in humans and chromosome 5 in mice, variable expression of the molecule due to hypermethylation and produces a protein product with relative molecular of the promoter region of the RELN gene or other unknown mass of 388 kDa. Reelin protein is localized to a number of mechanisms. Moreover, several non-CNS disorders have brain sites, specifically Cajal–Retzius cells located in layer 1 been associated with changes in expression of Reelin of neocortex, GABAergic interneurons, and cerebellar including several forms of cancers and otosclerosis. granule cells. Activation of the Reelin signaling pathway In the current issue, Teixeira and colleagues evaluated the leads to various, important functions such as enhancement effects of overexpression of Reelin in a transgenic mouse of long-term potentiation, cell proliferation, cell migration, model as compared with wild-type mice and to hetero- and more importantly dendritic spine morphogenesis. -
Plasminogen Activator Inhibitor 1 Functions As a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes MCF-7 Cell Growth Donna J
Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes MCF-7 Cell Growth Donna J. Webb, Keena S. Thomas, and Steven L. Gonias Department of Pathology, and Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia 22908 Abstract. Plasminogen activator inhibitor 1 (PAI-1) is association of Sos with Shc, whereas uPA caused tran- Downloaded from http://rupress.org/jcb/article-pdf/152/4/741/1297334/0011017.pdf by guest on 28 September 2021 a major inhibitor of urokinase-type plasminogen activa- sient association of Sos with Shc. tor (uPA). In this study, we explored the role of PAI-1 By sustaining ERK phosphorylation, PAI-1 con- in cell signaling. In MCF-7 cells, PAI-1 did not directly verted uPA into an MCF-7 cell mitogen. This activity activate the mitogen-activated protein (MAP) kinases, was blocked by receptor-associated protein and not ob- extracellular signal–regulated kinase (ERK) 1 and served with uPA–PAI-1R76E complex, demonstrating ERK2, but instead altered the response to uPA so the importance of the VLDLr. uPA promoted the that ERK phosphorylation was sustained. This effect growth of other cells in which ERK phosphorylation required the cooperative function of uPAR and the was sustained, including 3 integrin overexpressing very low density lipoprotein receptor (VLDLr). When MCF-7 cells and HT 1080 cells. The MEK inhibitor, MCF-7 cells were treated with uPA–PAI-1 complex in PD098059, blocked the growth-promoting activity of the presence of the VLDLr antagonist, receptor-associ- uPA and uPA–PAI-1 complex in these cells. -
Protein C Product Monograph 1995 COAMATIC® Protein C Protein C
Protein C Product Monograph 1995 COAMATIC® Protein C Protein C Protein C, Product Monograph 1995 Frank Axelsson, Product Information Manager Copyright © 1995 Chromogenix AB. Version 1.1 Taljegårdsgatan 3, S-431 53 Mölndal, Sweden. Tel: +46 31 706 20 00, Fax: +46 31 86 46 26, E-mail: [email protected], Internet: www.chromogenix.se COAMATIC® Protein C Protein C Contents Page Preface 2 Introduction 4 Determination of protein C activity with 4 snake venom and S-2366 Biochemistry 6 Protein C biochemistry 6 Clinical Aspects 10 Protein C deficiency 10 Assay Methods 13 Protein C assays 13 Laboratory aspects 16 Products 17 Diagnostic kits from Chromogenix 17 General assay procedure 18 COAMATIC® Protein C 19 References 20 Glossary 23 3 Protein C, version 1.1 Preface The blood coagulation system is carefully controlled in vivo by several anticoagulant mechanisms, which ensure that clot propagation does not lead to occlusion of the vasculature. The protein C pathway is one of these anticoagulant systems. During the last few years it has been found that inherited defects of the protein C system are underlying risk factors in a majority of cases with familial thrombophilia. The factor V gene mutation recently identified in conjunction with APC resistance is such a defect which, in combination with protein C deficiency, increases the thrombosis risk considerably. The Chromogenix Monographs [Protein C and APC-resistance] give a didactic and illustrated picture of the protein C environment by presenting a general view of medical as well as technical matters. They serve as an excellent introduction and survey to everyone who wishes to learn quickly about this field of medicine. -
PROTEIN C DEFICIENCY 1215 Adulthood and a Large Number of Children and Adults with Protein C Mutations [6,13]
Haemophilia (2008), 14, 1214–1221 DOI: 10.1111/j.1365-2516.2008.01838.x ORIGINAL ARTICLE Protein C deficiency N. A. GOLDENBERG* and M. J. MANCO-JOHNSON* *Hemophilia & Thrombosis Center, Section of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Colorado Denver and The ChildrenÕs Hospital, Aurora, CO; and Division of Hematology/ Oncology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA Summary. Severe protein C deficiency (i.e. protein C ment of acute thrombotic events in severe protein C ) activity <1 IU dL 1) is a rare autosomal recessive deficiency typically requires replacement with pro- disorder that usually presents in the neonatal period tein C concentrate while maintaining therapeutic with purpura fulminans (PF) and severe disseminated anticoagulation; protein C replacement is also used intravascular coagulation (DIC), often with concom- for prevention of these complications around sur- itant venous thromboembolism (VTE). Recurrent gery. Long-term management in severe protein C thrombotic episodes (PF, DIC, or VTE) are common. deficiency involves anticoagulation with or without a Homozygotes and compound heterozygotes often protein C replacement regimen. Although many possess a similar phenotype of severe protein C patients with severe protein C deficiency are born deficiency. Mild (i.e. simple heterozygous) protein C with evidence of in utero thrombosis and experience deficiency, by contrast, is often asymptomatic but multiple further events, intensive treatment and may involve recurrent VTE episodes, most often monitoring can enable these individuals to thrive. triggered by clinical risk factors. The coagulopathy in Further research is needed to better delineate optimal protein C deficiency is caused by impaired inactiva- preventive and therapeutic strategies. -
Lab Dept: Coagulation Test Name: PROTEIN C CHROMOGENIC
Lab Dept: Coagulation Test Name: PROTEIN C CHROMOGENIC General Information Lab Order Codes: PRC Protein C Activity Assay; Protein C Immunologic Assay Synonyms: 85303 – Clotting inhibitors or anticoagulants; Protein C activity CPT Codes: Test Includes: Protein C activity Logistics Protein C, along with its cofactor Protein S, acts as a potent anticoagulant Test Indications: by destroying activated Factors 5 and 8. It also stimulates the fibrinolytic system. It is Vitamin K dependent, therefore it is decreased in coumadin therapy or Vitamin K deficiency. Protein C deficiency is a risk factor for thromboembolism. Severe deficiency may cause purpura fulminans in neonates. Incident to a thrombotic event, both procoagulant and regulatory coagulation proteins may be lower than basal state due to excessive consumption or higher than basal state from reactive overproduction. Therefore, it is best not to test for Protein C deficiency during an acute thrombotic event. The Protein C antigen test determines the amount of the molecule present, not its functionality. The Protein C Chromogenic (activity) assay determines the functionality. Therefore, the Protein C Chromogenic (activity) assay is the preferred method. Lab Testing Sections: Coagulation (Minneapolis Campus) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours Turnaround Time: 1 – 7 days, performed on Fridays Special Instructions: Elective testing for Protein C deficiency is best done at least 30 days after cessation of Coumadin® therapy. Protein C may be reduced during an acute event (thrombotic, surgical, etc.) therefore it is preferable not to test for it during this time. However a normal value at the time of an acute event excludes a congenital deficiency.